Literature DB >> 19622768

CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer.

Marleen M Welsh1, Katie M Applebaum, Steven K Spencer, Ann E Perry, Margaret R Karagas, Heather H Nelson.   

Abstract

Although skin tumors are highly immunogenic, exposure to UV radiation is known to suppress immune responses via regulatory T cells. Specifically, the activity of cytotoxic lymphocyte-associated antigen-4 (CTLA-4) is integral in regulating the development of UV-induced tolerance and, concomitantly, skin cancers. Due to the inverse relationship between tumor surveillance and autoimmunity, we hypothesize that the same genetic variant in the CTLA4 locus that increases risk for autoimmune diseases is associated with decreased risk of non-melanoma skin cancer (NMSC). We analyzed whether the polymorphism CT60 or haplotypes of CTLA4 influence odds of developing the major types of NMSC, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), in a population-based case-control study of Caucasians in New Hampshire (849 controls, 930 BCC, and 713 SCC). The CTLA4 CT60 GG genotype was associated with decreased odds for BCC and SCC, controlling for age, sex, lifetime number of severe sunburns, and skin type [BCC: odds ratio (OR), 0.7; 95% confidence interval (95% CI), 0.5-0.9; SCC: OR, 0.7; 95% CI, 0.5-1.0]. For BCC, this decrease was apparent largely among those with a higher lifetime number of severe sunburns (P(interaction) = 0.0074). There were significantly decreased odds of disease associated with two haplotypes, which possess the CT60 G allele. Additionally, lifetime number of severe sunburns modestly altered the effects of the CTLA4 haplotypes in BCC, and the association seemed driven by the CT60 single nucleotide polymorphism. In conclusion, genetic variation at the CTLA4 locus may be etiologically important in NMSC, the most prevalent malignancy in the United States.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622768      PMCID: PMC2928067          DOI: 10.1158/0008-5472.CAN-09-0415

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Can skin cancers be minimized or prevented in organ transplant patients?

Authors:  J McCann
Journal:  J Natl Cancer Inst       Date:  1999-06-02       Impact factor: 13.506

2.  Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group.

Authors:  M R Karagas; E R Greenberg; S K Spencer; T A Stukel; L A Mott
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

Review 3.  The B7 family revisited.

Authors:  Rebecca J Greenwald; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

4.  Association of CTLA4 polymorphism with regulatory T cell frequency.

Authors:  Sowsan F Atabani; Chloe L Thio; Senad Divanovic; Aurelien Trompette; Yasmine Belkaid; David L Thomas; Christopher L Karp
Journal:  Eur J Immunol       Date:  2005-07       Impact factor: 5.532

5.  Evidence for the generation of suppressor cells by ultraviolet radiation.

Authors:  R A Daynes; C W Spellman
Journal:  Cell Immunol       Date:  1977-06-01       Impact factor: 4.868

Review 6.  CTLA4 gene polymorphism and autoimmunity.

Authors:  Stephen C L Gough; Lucy S K Walker; David M Sansom
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

7.  Immunologic parameters of ultraviolet carcinogenesis.

Authors:  M L Kripke; M S Fisher
Journal:  J Natl Cancer Inst       Date:  1976-07       Impact factor: 13.506

8.  Suppression of contact hypersensitivity in mice by ultraviolet irradiation is associated with defective antigen presentation.

Authors:  F P Noonan; M L Kripke; G M Pedersen; M I Greene
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

9.  Effects of ultraviolet B light on cutaneous immune responses of humans with deeply pigmented skin.

Authors:  M Vermeer; G J Schmieder; T Yoshikawa; J W van den Berg; M S Metzman; J R Taylor; J W Streilein
Journal:  J Invest Dermatol       Date:  1991-10       Impact factor: 8.551

10.  Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer.

Authors:  N Erfani; M Razmkhah; A R Talei; A M Pezeshki; M Doroudchi; A Monabati; A Ghaderi
Journal:  Cancer Genet Cytogenet       Date:  2006-03
View more
  19 in total

Review 1.  Autoimmune effector memory T cells: the bad and the good.

Authors:  Priyadharshini Devarajan; Zhibin Chen
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  Niacin intake and risk of skin cancer in US women and men.

Authors:  Sang Min Park; Tricia Li; Shaowei Wu; Wen-Qing Li; Martin Weinstock; Abrar A Qureshi; Eunyoung Cho
Journal:  Int J Cancer       Date:  2017-02-14       Impact factor: 7.396

3.  The influence of aging, environmental exposures and local sequence features on the variation of DNA methylation in blood.

Authors:  Scott M Langevin; E Andres Houseman; Brock C Christensen; John K Wiencke; Heather H Nelson; Margaret R Karagas; Carmen J Marsit; Karl T Kelsey
Journal:  Epigenetics       Date:  2011-07-01       Impact factor: 4.528

4.  A Genome-Wide Association Study of Cutaneous Squamous Cell Carcinoma among European Descendants.

Authors:  Satu J Siiskonen; Mingfeng Zhang; Wen-Qing Li; Liming Liang; Peter Kraft; Tamar Nijsten; Jiali Han; Abrar A Qureshi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-12       Impact factor: 4.254

5.  Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?

Authors:  Lidia Karabon; K Tupikowski; A Tomkiewicz; A Partyka; E Pawlak-Adamska; A Wojciechowski; A Kolodziej; J Dembowski; R Zdrojowy; I Frydecka
Journal:  Pathol Oncol Res       Date:  2017-01-18       Impact factor: 3.201

6.  History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience.

Authors:  Rossybelle P Amorrortu; Yayi Zhao; Sandra Stewart; Kavita M Ghia; Vonetta L Williams; Vernon K Sondak; Kenneth Y Tsai; Javier Pinilla; Julio Chavez; Dana E Rollison
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-13       Impact factor: 4.322

Review 7.  Antibody-based immunotherapy for malignant glioma.

Authors:  Patrick C Gedeon; Katherine A Riccione; Peter E Fecci; John H Sampson
Journal:  Semin Oncol       Date:  2014-06-12       Impact factor: 4.929

8.  Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk.

Authors:  H-Y Zhao; H-X Duan; Y Gu
Journal:  Clin Transl Oncol       Date:  2014-02-04       Impact factor: 3.405

9.  Association between the Cytotoxic T-lymphocyte antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis.

Authors:  Jian Zheng; Xiao Yu; Lan Jiang; Mang Xiao; Bing Bai; Jiachun Lu; Yifeng Zhou
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

10.  Lack of association between cytotoxic T-lymphocyte antigen 4 (CTLA-4) -1722T/C (rs733618) polymorphism and cancer risk: from a case-control study to a meta-analysis.

Authors:  Weifeng Tang; Hao Qiu; Heping Jiang; Bin Sun; Lixin Wang; Jun Yin; Haiyong Gu
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.